z-logo
open-access-imgOpen Access
Phase I EnACT Trial of the Safety and Tolerability of a Novel Oral Formulation of Amphotericin B
Author(s) -
Caleb P Skipper,
Mucunguzi Atukunda,
Anna Stadelman,
Nicole Engen,
Ananta S Bangdiwala,
Katherine Huppler Hullsiek,
Mahsa Abassi,
Joshua Rhein,
Melanie Nicol,
Eva Laker,
Darlisha A Williams,
Raphael J. Mannino,
Theresa Matkovits,
David B. Meya,
David R. Boulware
Publication year - 2020
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.00838-20
Subject(s) - tolerability , amphotericin b , amphotericin b deoxycholate , bioavailability , pharmacokinetics , pharmacology , medicine , toxicity , drug , adverse effect , antifungal , dermatology , caspofungin
Amphotericin B deoxycholate (AMB) has substantial toxicities. A novel encochleated amphotericin B deoxycholate (cAMB) formulation has oral bioavailability, efficacy in an animal model, and minimal toxicity due to targeted drug delivery into macrophages, where intracellular fungi reside. We conducted a phase I, ascending-dose trial of cAMB administered at 1.0 g, 1.5 g, or 2.0 g per day in 4 to 6 divided doses among HIV-positive survivors of cryptococcosis ( n  = 9 per cohort). We assessed the tolerability of cAMB and the adverse events (AEs) associated with cAMB treatment over 3 days. A second trial ( n  = 9) assessed the tolerability of 1.5 g/day given for 7 days. In the single-ascending-dose study, all subjects received their full daily dose without vomiting (100% tolerability). The cohort receiving 1.0 g had 4 transient clinical AEs in 2 subjects within 48 h and 8 laboratory AEs ( n  = 6 grade 2, n  = 2 grade 1). The cohort receiving 1.5 g had 7 clinical AEs in 1 subject attributed to acute gastroenteritis ( n  = 4 grade 2) and 5 laboratory AEs ( n  = 1 grade 2). The cohort receiving 2.0 g had 20 clinical AEs among 5 subjects within 48 h ( n  = 3 grade 2) and 11 laboratory AEs ( n  = 2 grade 2, n  = 1 grade 3). From a qualitative survey, 26 of 27 subjects (96%) preferred their experience with oral cAMB over their prior experience with intravenous (i.v.) AMB. The second, multiple-dose cohort received 1.5 g/day for 1 week, with 98.4% (248/252) of the doses being taken. Overall, 5 clinical AEs ( n  = 5 grade 1) and 6 laboratory AEs ( n  = 6 grade 1) occurred without kidney toxicity. Oral cAMB was well tolerated when given in 4 to 6 divided daily doses without the toxicities commonly seen with i.v. AMB. (This study has been registered at ClinicalTrials.gov under registration no. NCT04031833.).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here